Evidence map›Paper›PMID 38433846›Full record

ArticleFrontiers in immunology2024

B cell repertoire sequencing of HIV-1 pediatric elite-neutralizers identifies multiple broadly neutralizing antibody clonotypes.

Sanjeev Kumar, Prashant Bajpai, Collin Joyce, Sushil Kumar Kabra, Rakesh Lodha, Dennis R Burton, Bryan Briney, Kalpana Luthra

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Sanjeev Kumar *Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Prashant Bajpai *International Centre for Genetic Engineering and Biotechnology (ICGEB)-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, India.
Collin JoyceDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
Sushil Kumar KabraDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Rakesh LodhaDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
Bryan BrineyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
Kalpana LuthraDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · INScripps Research Institute · USInternational AIDS Vaccine Initiative · USInternational Centre for Genetic Engineering and Biotechnology · IN

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
The Multi-omics Vaccine Evaluation (MOVE) ConsortiumP01AI177683 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Laura D. Hughes · 2023 to 2026
$9.0M
High-resolution deconvolution of selection effects on the composition of the B cell repertoireR35GM133682 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI BRINEY, BRYAN · 2019 to 2023
$2.4M
DBT-Wellcome Trust India Alliance IA/E/18/1/504307NIAID NIH HHS P01 AI177683NIAID NIH HHS P30 AI036214NIAID NIH HHS UM1 AI144462NIGMS NIH HHS R35 GM133682Wellcome Trust
6 · The paper itself

Abstract

Introduction: A limited subset of HIV-1 infected adult individuals typically after at least 2-3 years of chronic infection, develop broadly neutralizing antibodies (bnAbs), suggesting that highly conserved neutralizing epitopes on the HIV-1 envelope glycoprotein are difficult for B cell receptors to effectively target, during natural infection. Recent studies have shown the evolution of bnAbs in HIV-1 infected infants. Methods: We used bulk BCR sequencing (BCR-seq) to profile the B cell receptors from longitudinal samples (3 time points) collected from a rare pair of antiretroviralnaïve, HIV-1 infected pediatric monozygotic twins (AIIMS_329 and AIIMS_330) who displayed elite plasma neutralizing activity against HIV-1. Results: BCR-seq of both twins revealed convergent antibody characteristics including V-gene use, CDRH3 lengths and somatic hypermutation (SHM). Further, antibody clonotypes with genetic features similar to highly potent bnAbs isolated from adults showed ongoing development in donor AIIMS_330 but not in AIIMS_329, corroborating our earlier findings based on plasma bnAbs responses. An increase in SHM was observed in sequences of the IgA isotype from AIIMS_330. Discussion: This study suggests that children living with chronic HIV-1 can develop clonotypes of HIV-1 bnAbs against multiple envelope epitopes similar to those isolated from adults, highlighting that such B cells could be steered to elicit bnAbs responses through vaccines aimed to induce bnAbs against HIV-1 in a broad range of people including children.

Indexed as

HIV-1HIV SeropositivityAdultAntibodiesAntigens, ViralBroadly Neutralizing AntibodiesChildEpitopesHumansInfantReceptors, Antigen, B-CellTwins, MonozygoticAntibodiesAntigens, ViralBroadly Neutralizing AntibodiesEpitopesReceptors, Antigen, B-CellB cell repertoire sequencingbnAbschildrenclonotypeselite-neutralizersHIV-1

Identifiers

PMID38433846
PMCPMC10905035
OpenAlexW4391882428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.